Products
Tigilanol tiglate was approved in the EU and many countries in 2020 as a solution for injection in dogs (Stelfonta). It is a veterinary medicinal product.
Structure and properties
Tigilanol tiglate (C30H42O10, Mr = 562.6 g/mol) is a diterpene ester (an epoxytiglian). It is extracted from the seeds of , a shrub or tree in the spurge family (Euphorbiaceae) native to the Australian rainforest.
Effects
Tigilanol tiglate (ATCvet QL01XX91) has antitumor and cytotoxic properties. The effects are due to activation of the protein kinase C (PKC) signaling cascade. Tigilanol tiglate leads to loss of tumor blood vessel integrity, tumor cell death, and a rapid and local inflammatory response. This triggers necrosis and decomposition of the tumor mass.
Indications
For the treatment of mast cell tumors in dogs.
Dosage
According to the SmPC. Tigilanol tiglate is administered directly into the tumor (intratumorally). It is locally active and not systemically active.
Contraindications
- Hypersensitivity
- Mast cell tumors with a damaged surface
- Do not administer directly into the resection margins after surgical removal of a tumor.
Refer to the drug label for complete precautions.
Interactions
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) is not recommended.
Adverse effects
The most common possible adverse effects include:
- Pain during injection
- Wound formation at the injection site associated with pain and lameness
- Vomiting
- Fast heart rate
- Lethargy
